Atlas Trials

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Clinical trial NCT05756569 · RECRUITING

Trial details

NCT number
NCT05756569
Sponsor
Emory University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Squamous Cell CarcinomaLocally Advanced Bladder CarcinomaMalignant Renal Pelvis NeoplasmMalignant Ureter NeoplasmMalignant Urethral NeoplasmMetastatic Bladder CarcinomaStage III Bladder Cancer AJCC v8Stage IV Bladder Cancer AJCC v8Unresectable Bladder CarcinomaUrachal AdenocarcinomaBladder Adenocarcinoma
Start date
2023-09-26
Primary completion
2026-12-16
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.